MNV
Market News Video
MNV MNV 10 Oversold Stocks You Need To Know About
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

iShares U.S. Pharmaceuticals Getting Very Oversold
Thursday, October 26, 4:10 PM ET, by Market News Video Staff

In trading on Thursday, shares of the iShares U.S. Pharmaceuticals ETF (IHE) entered into oversold ...

IHE Crosses Above Key Moving Average Level
Wednesday, November 1, 11:04 AM ET, by Market News Video Staff

In trading on Wednesday, shares of the iShares U.S. Pharmaceuticals ETF (IHE) crossed above their ...

IHE's Holdings Imply 26% Gain Potential
Thursday, November 2, 8:33 AM ET, by Market News Video Staff

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...

TherapeuticsMD is Now Oversold (TXMD)
Friday, November 3, 4:23 PM ET, by Market News Video Staff

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...

Investors Snag ACRS Even Lower Than Its Secondary Stock Offering
Tuesday, November 7, 11:12 AM ET, by Market News Video Staff

Looking back to 89 days ago, Aclaris Therapeutics Inc (ACRS) priced a 3,260,000 share secondary ...

  More articles:  1 2 next »

ACRS Makes Bullish Cross Above Critical Moving Average

By Market News Video Staff, Friday, January 12, 11:55 AM ET
Play Video: Learn About The 200 DMA


If the video does not load after a few moments, Upgrade to the Latest Flash Player.

In trading on Friday, shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) crossed above their 200 day moving average of $26.13, changing hands as high as $26.25 per share. Aclaris Therapeutics Inc shares are currently trading up about 2.9% on the day. The chart below shows the one year performance of ACRS shares, versus its 200 day moving average:

Aclaris Therapeutics Inc 200 Day Moving Average Chart

Looking at the chart above, ACRS's low point in its 52 week range is $21.32 per share, with $33.25 as the 52 week high point that compares with a last trade of $26.23.


Special Offer: Join the income investing conversation on ValueForum.com with a special Seven Days for Seven Dollars invitation.

According to the ETF Finder at ETF Channel, ACRS makes up 1.04% of the iShares U.S. Pharmaceuticals ETF (AMEX:IHE) which is trading up by about 0.6% on the day Friday.

See what other ETFs contain ACRS
See what other stocks are held by IHE


Top Six Most Viewed Stories This Week @ Market News Video:

This Article's Word Cloud:   ACRS   AMEX   Above   According   Aclaris   Crossing   Days   ETFs   Finder   Friday   Looking   Pharmaceuticals   Seven   Special   Start   Stocks   Their   Therapeutics   ValueForum   about   above   average   below   changing   chart   compares   currently   held   high   iShares   income   investing   last   makes   moving   other   point   range   raquo   share   shares   slideshow   that   trading   versus   week   what   which   with   year
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy - Video Widget
MNV
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Portfolio Channel Stock Market Definitions
MNV

ACRS Makes Bullish Cross Above Critical Moving Average | Market News Video | Copyright © 2008 - 2018, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.